Nitric oxide and pulmonary arterial hypertension

Adrian H Chester, Magdi H Yacoub, Salvador Moncada

Abstract


The pathogenesis of pulmonary arterial hypertension remains undefined. Changes in the expression and effects mediated by a number of vasoactive factors have been implicated to play a role in the onset and progression of the disease. The source of many of these mediators, such as nitric oxide (NO), prostacyclin and endothelin-1 (ET-1), is the pulmonary endothelium. This article focus in the role of nitric oxide in PAH, reviewing the evidence for its involvement in regulation of pulmonary a vascular tone under physiological conditions, the mechanisms by which it can contribute to the pathological changes seen in PAH and strategies for the use of NO as a therapy for treatment of the disease. 


Full Text:

PDF


DOI: http://dx.doi.org/10.21542/gcsp.2017.14

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 Adrian H Chester, Magdi H Yacoub, Salvador Moncada

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.